Halozyme Therapeutics, Inc. (HALO): A Bull Case Theory [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
Halozyme Therapeutics, Inc.'s share was trading at $70.98 as of February 20th. HALO's trailing and forward P/E were 16.41 and 8.19, respectively according to Yahoo Finance. Morgan Stanley Lifted GE HealthCare Target to $80 in Late October, Citing Strong Orders and Backlog Wichy/Shutterstock.com Halozyme Therapeutics Inc (HALO), based in San Diego, California, is a pharmaceutical technology company that has built a high-margin, royalty-driven business by transforming complex IV biologics into simple, rapid subcutaneous injections. Its flagship ENHANZE platform has revolutionized treatments such as DARZALEX SC, Phesgo, and VYVGART Hytrulo, cutting multi-hour cancer and autoimmune therapies down to five-minute or patient-administerable doses. This proprietary technology provides Halozyme with a durable, annuity-like revenue stream that is insulated from typical biotech R&D risk, while offering substantial earnings visibility. The company's royalty model, tied to blockbuster drugs
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Halozyme Appoints Darren Snellgrove as Chief Financial OfficerPR Newswire
- Halozyme Therapeutics (HALO) had its price target raised by HC Wainwright from $90.00 to $95.00. They now have a "buy" rating on the stock.MarketBeat
- Is Halozyme Therapeutics (HALO) Offering Value After Mixed Multi Year Share Price Performance [Yahoo! Finance]Yahoo! Finance
- Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ TechnologyPR Newswire
- How The Investment Story Is Shifting For Halozyme Therapeutics (HALO) After Recent Analyst Calls [Yahoo! Finance]Yahoo! Finance
HALO
Earnings
- 2/17/26 - Miss
HALO
Sec Filings
- 4/30/26 - Form 8-K
- 4/24/26 - Form 8-K
- 4/7/26 - Form 4
- HALO's page on the SEC website